|Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients (Replay)06/28/17 at 4:30 p.m. ET|
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>
NASDAQ | GEMP (Common Stock)
06/28/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Press Releases More
Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients06/28/17
Gemphire to Present at the LD Micro Invitational and the Jefferies 2017 Global Healthcare Conference06/01/17
Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch05/30/17
Investor Events More
There are currently no events scheduled.